CME Monograph: Understanding Osteoarthritis Today Moving Beyond Symptom Control

Understanding Osteoarthritis Today
Moving Beyond Symptom Control
to Disease Modification



	How to Obtain AMA PRA Category 1 Credit™ Read the CME monograph. Complete the CME posttest (each question must be answered correctly). Login to your account. Complete the credit and evaluation form. Print your personalized CME certificate. Technical Requirements

Release Date: June 17, 2011
Expiration Date: June 17, 2012

Estimated Time of Completion: 1 hour

Description

This monograph features an outstanding faculty of OA experts who review and debate the impact of research innovations and treatment developments. These innovations have the potential to transition current practice strategies from a symptomatic tactic to a more comprehensive disease treatment approach.

Osteoarthritis (OA) management is transitioning from a focus on symptom control to disease modification. Early detection and intervention are essential to this process. These changes in the clinical landscape have the potential to improve outcomes in a growing patient population that has jumped by more than one-third in the last decade, with nearly 27 million Americans now diagnosed.

Learning Objectives

Identify epidemiologic changes in OA and discuss their impact on clinical practice.
Assess efficacy and safety data from clinical trials of disease-modifying OA drugs (DMOADs) and gauge their potential impact on clinical practice.
Discuss new and emerging pain modulators as they apply to management of patients with OA.
Discuss the updated pathophysiology of OA.

Target Audience

This monograph is intended for rheumatologists, rheumatology fellows, and other interested health care professionals.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Creditsä. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.

Activity Director

M. Elaine Husni, MD, MPH
Assistant Professor
Cleveland Clinic Lerner College of Medicine of Case Western Reserve University
Director, Clinical Outcomes Research
Director, Arthritis and Musculoskeletal Treatment Center
Department of Rheumatic and Immunologic Diseases
Orthopaedic and Rheumatologic Institute
Cleveland Clinic
Cleveland, OH

Faculty

Steven Abramson, MD Professor of Medicine and Pathology Director, Division of Rheumatology Vice President and Senior Vice Dean for Education Faculty and Academic Affairs New York University School of Medicine New York, NY	Roland W. Moskowitz, MD Clinical Professor of Medicine University Hospitals Case Medical Center Cleveland, OH
Clifton O. Bingham III, MD Associate Professor of Medicine Divisions of Rheumatology and Allergy and Clinical Immunology Johns Hopkins University Baltimore, MD	Thomas J. Schnitzer, MD, PhD Professor of Medicine Northwestern University Feinberg School of Medicine Departments of Physical Medicine and Rehabilitation and Internal Medicine/Rheumatology Chicago, IL

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:

Clifton Bingham, MD
	Consulting:	Abbott Laboratories; Genentech; Novartis; Roche Laboratories; UCB
	Educational grant support:	Abbott Laboratories; Amgen; Bristol Myers; Genentech; Roche Laboratories; Wyeth

	Independent contractor (including contracted research):	Bristol Myers; Genentech; Roche Laboratories; UCB

Thomas Schnitzer, MD
	Consulting:	Abbott Laboratories, Covidien; Logical Therapeutics; Merck & Co, Inc.; NicOx; Novartis; Sanofi-Aventis; Stryker; Takeda
	Ownership interest (stock, stock options):	NicOx

The following faculty have indicated they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest:

Steven Abramson, MD
M. Elaine Husni, MD, MPH
Roland Moskowitz, MD

All other planners, CME staff, and content reviewers have no relevant financial relationship to disclose.

The Cleveland Clinic Foundation Center for Continuing Education acknowledges
an educational grant for support of this activity from:
Mallinckrodt, a Covidien company

This CME activity was produced by The Cleveland Clinic Foundation
Center for Continuing Education and the Department of Rheumatic and Immunologic Diseases.

CME Disclaimer

Understanding Osteoarthritis Today Moving Beyond Symptom Control to Disease Modification